Journal of Comparative Effectiveness Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Study Protocol for the Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence (SISTER) study: a community engaged national randomized trial
Discussion/conclusion: Endometrial cancer mortality disproportionately affects Black women, and social isolation contributes to this disparity. The SISTER study aims to identify whether and to what extent differing social support vehicles improve key outcomes for Black women in the United States with high-risk EC. Clinical Trial Registration: NCT04930159 (ClinicalTrials.gov).PMID:38348827 | DOI:10.57264/cer-2023-0159 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - February 13, 2024 Category: General Medicine Authors: Ann Oluloro Bryan Comstock Sarah E Monsell Maya Gross Erika M Wolff Liz Sage Julianna Alson Danielle C Lavallee Bridgette Hempstead Adrienne Moore Ronit Katz Kemi M Doll Source Type: research
Real-world data analysis of bilayered living cellular construct and fetal bovine collagen dressing treatment for pressure injuries: a comparative effectiveness study
Conclusion: BLCC significantly improved healing of PRIs versus FBCD.PMID:38348818 | DOI:10.57264/cer-2023-0109 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - February 13, 2024 Category: General Medicine Authors: Michael L Sabolinski Tad Archambault Source Type: research
Study Protocol for the Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence (SISTER) study: a community engaged national randomized trial
Discussion/conclusion: Endometrial cancer mortality disproportionately affects Black women, and social isolation contributes to this disparity. The SISTER study aims to identify whether and to what extent differing social support vehicles improve key outcomes for Black women in the United States with high-risk EC. Clinical Trial Registration: NCT04930159 (ClinicalTrials.gov).PMID:38348827 | DOI:10.57264/cer-2023-0159 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - February 13, 2024 Category: General Medicine Authors: Ann Oluloro Bryan Comstock Sarah E Monsell Maya Gross Erika M Wolff Liz Sage Julianna Alson Danielle C Lavallee Bridgette Hempstead Adrienne Moore Ronit Katz Kemi M Doll Source Type: research
Acceptability and consumers' willingness to pay for comprehensive medication management services in Brazil
Conclusion: The research results show that most people are willing to pay for the CMM service. This study can contribute to the decision-making regarding the implementation and pricing of the service in Brazil.PMID:38329429 | DOI:10.57264/cer-2023-0127 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - February 8, 2024 Category: General Medicine Authors: Lucas Lima T ôrres P âmela Santos Azevedo T úlio Tadeu Rocha Sarmento Djenane Ramalho-de-Oliveira Edna Afonso Reis Isabella Piassi Dias God ói Augusto Afonso Guerra J únior Cristina Mariano Ruas Source Type: research
Access in all areas? A round up of developments in market access and health technology assessment: part 3
J Comp Eff Res. 2024 Feb 8:e240009. doi: 10.57264/cer-2024-0009. Online ahead of print.ABSTRACTIn this latest update, we explore some of the key updates in market access over recent months including the UK's voluntary scheme for branded medicines pricing, access and growth (VPAG), the first drugs funded by the Innovative Medicines Fund in the UK and the Direct Access Scheme in France, and, finally, the new Institute for Clinical and Economic Review (ICER) value assessment framework in the USA.PMID:38329446 | DOI:10.57264/cer-2024-0009 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - February 8, 2024 Category: General Medicine Authors: Alice Beattie Catrin Treharne Sreeram V Ramagopalan Source Type: research
Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
Conclusion: Switching from TDF to TAF in patients living with CHB is a cost effective strategy to reduce adverse liver disease outcomes, while improving bone- and renal-related safety outcomes.PMID:38317634 | DOI:10.57264/cer-2023-0090 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - February 6, 2024 Category: General Medicine Authors: Emmanouil Sinakos Nandita Kachru Christos Tsoulas Sushanth Jeyakumar Nathaniel J Smith Alon Yehoshua Evangelos Cholongitas Source Type: research
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France
Conclusion: The use of rt-CGM is likely to be cost-effective versus SMBG for people with insulin-treated Type II diabetes in France.PMID:38294332 | DOI:10.57264/cer-2023-0174 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 31, 2024 Category: General Medicine Authors: Hamza Alshannaq Richard F Pollock Michael Joubert Waqas Ahmed Gregory J Norman Peter M Lynch St éphane Roze Source Type: research
Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA
Conclusion: Findings indicate that treatment type and timing can affect SPM development in patients with CLL. Combined with previous findings, this can help inform best practices in monitoring for SPM in patients with CLL.PMID:38294335 | PMC:PMC10842294 | DOI:10.57264/cer-2023-0119 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 31, 2024 Category: General Medicine Authors: Sikander Ailawadhi Arliene Ravelo Carmen D Ng Bonny Shah Neil Lamarre Rongrong Wang Katherine Eakle Juliana Ml Biondo Source Type: research
Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study
Conclusion: In a real-world setting, this sub-analysis in Bangladeshi patients shows that patients with T2DM treated with gliclazide MR 60 mg can fast safely during Ramadan with a very low risk of hypoglycemia, while maintaining glycemic control and body weight.PMID:38294337 | PMC:PMC10842293 | DOI:10.57264/cer-2023-0132 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 31, 2024 Category: General Medicine Authors: Mohammed Farid Uddin Murshed Ahamed Khan Shahjada Selim Nusrat Sultana Mohammad Abu Sayem Mohammed Mahboob Iftekhar Maruf Bin Habib Nazma Akter Shahjamal Khan Source Type: research
A US national update of health condition prevalence among privately-insured autistic adults
Discussion & conclusion: Our use of a large US national sample, more recent healthcare claims data, and different methods for identifying health conditions may have contributed to these differences. Our findings alert healthcare providers and policymakers to the health conditions most common among the growing population of autistic adults. We hope these findings lead to improved screening and management of these conditions, inform initiatives to improve access to healthcare, and guide future funding.PMID:38294339 | DOI:10.57264/cer-2023-0051 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 31, 2024 Category: General Medicine Authors: Anne Longo Deondray Radford Brittany N Hand Source Type: research
Distinguishing cardiac catheter ablation energy modalities by applying natural language processing to electronic health records
Conclusion: NLP has potential to evaluate the frequency of cardiac ablation by type, however, for this to be a reliable real-world data source, mandatory data entry by providers and standardized electronic health reporting must occur.PMID:38261335 | DOI:10.57264/cer-2023-0053 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 23, 2024 Category: General Medicine Authors: Jamie Margetta Alicia Sale Source Type: research
Visualizing the target estimand in comparative effectiveness studies with multiple treatments
Conclusion: Visualization tools may help to clarify the target population in comparative effectiveness studies and resolve ambiguity about the interpretation of estimated treatment effects.PMID:38261336 | PMC:PMC10842272 | DOI:10.57264/cer-2023-0089 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 23, 2024 Category: General Medicine Authors: Gabrielle Simoneau Marian Mitroiu Thomas Pa Debray Wei Wei Stan Rw Wijn Joana Caldas Magalh ães Justin Bohn Changyu Shen Fabio Pellegrini Carl de Moor Source Type: research
Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment
Conclusion: Three methods were used to estimate utilities for NASH, each one showed sensitivity to advancing fibrosis, including in the early stages, which is often considered asymptomatic.PMID:38226909 | PMC:PMC10842270 | DOI:10.57264/cer-2023-0033 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 16, 2024 Category: General Medicine Authors: Daniel Aggio Katy Gallop Villum Wittrup-Jensen Soulmaz Fazeli Farsani Andrew J Lloyd Source Type: research
Navigating the unknown: how to best 'reflect' standard of care in indications without a dedicated treatment pathway in health technology assessment submissions
J Comp Eff Res. 2024 Feb;13(2):e230145. doi: 10.57264/cer-2023-0145. Epub 2024 Jan 16.ABSTRACTThere is an urgent need for expedited approval and access for new health technologies targeting rare and very rare diseases, some of which are associated with high unmet treatment needs. Once a new technology achieves regulatory approval, the technology needs to be assessed by health technology assessment (HTA) bodies to inform coverage and reimbursement decisions. This assessment quantitatively examines the clinical effectiveness, safety and/or economic impact of the new technology relative to standard of care (SoC) in a specific...
Source: Journal of Comparative Effectiveness Research - January 16, 2024 Category: General Medicine Authors: Grammati Sarri Maria Rizzo Sheela Upadhyaya Victoria Federico Paly Luis Hernandez Source Type: research
Corrigendum
J Comp Eff Res. 2024 Jan 16:e240003c1. doi: 10.57264/cer-2024-0003. Online ahead of print.NO ABSTRACTPMID:38226925 | DOI:10.57264/cer-2024-0003 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 16, 2024 Category: General Medicine Source Type: research